PD-169316

PD-169316 is a potent, selective, and cell-permeable small molecule inhibitor of p38 mitogen‑activated protein kinase (MAPK), with an IC50 of approximately 89 nM. It selectively inhibits the kinase activity of phosphorylated p38 MAPK without affecting upstream kinases. PD‑169316 has been shown to block signal transduction mediated by transforming growth factor beta (TGF‑β) and Activin A but not bone morphogenetic protein 4 (BMP‑4). In preclinical studies, it demonstrates antiviral activity against Enterovirus71 by dampening viral replication and reducing inflammatory cytokine release. Additionally, it exhibits neuroprotective effects in animal models of Alzheimer's disease by reducing apoptosis markers following amyloid β exposure[1][3][8][5]. The compound is used primarily as a research tool; no clinical trials or approved therapeutic uses are reported.

Other names

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazolePyridine, 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]-CAS 152121-53-4CAS152121-53-4CAS-152121-53-4